Formalin fixed, paraffin-embedded tumor tissue blocks from cancer patients are stockpiled in pathology labs throughout the world. These tissues blocks contain the secrets of oncogenes, their relationship to carcinogenesis and their response to therapy. The overall specific aim of this proposal, is to determine the feasibility of developing in situ hybridization technology for detection of oncogene RNAs in these fixed tissues. Phase I will take advantage of the fact that N-myc exhibits both elevated RNA expression and amplified gene copy number in neuroblastoma; neuroepithelioma will serve as a negative control. Together they provide a standardized system to evaluate the effects of various in situ hybridization conditions. Fresh tumor tissue will be obtained by propogating human cell lines in nude mice. It is anticipated that the biggest problem will be sensitivity. The use of RNA rather that DNA probes will allow for a post- hybridization RNase treatment to reduce backgrounds and permit detection of RNA expression at very low levels in individual cells. Many of the current steps for in situ hybridization to frozen sections and cytospins do not give optimum results with fixed, paraffin-embedded sections. The various treatments work Interactively to give an overall sensitivity level; therefore, a multidimensional array of tissue and slide treatments will be examined to maximize sensitivity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA043349-01A1
Application #
3491526
Study Section
(SSS)
Project Start
1987-09-15
Project End
1988-03-14
Budget Start
1987-09-15
Budget End
1988-03-14
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Oncorpharm, Inc.
Department
Type
DUNS #
City
Gaithersburg
State
MD
Country
United States
Zip Code
20877